Lucie Jolly

Nancy, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

The potential of targeting TREM-1 in IBD.

The potential of targeting TREM-1 in IBD.

Journal: Advances in pharmacology (San Diego, Calif.)

Published: November 09, 2024

Soluble TREM-1 plasma concentration predicts poor outcome in COVID-19 patients.

Soluble TREM-1 plasma concentration predicts poor outcome in COVID-19 patients.

Journal: Intensive care medicine experimental

Published: April 21, 2023

Dexamethasone Modulates the Cytokine Response but Not COVID-19-Induced Coagulopathy in Critically Ill.

Dexamethasone Modulates the Cytokine Response but Not COVID-19-Induced Coagulopathy in Critically Ill.

Journal: International journal of molecular sciences

Published: March 02, 2023

Persistently Elevated Soluble Triggering Receptor Expressed on Myeloid Cells 1 and Decreased Monocyte Human Leucocyte Antigen DR Expression Are Associated With Nosocomial Infections in Septic Shock Patients.

Persistently Elevated Soluble Triggering Receptor Expressed on Myeloid Cells 1 and Decreased Monocyte Human Leucocyte Antigen DR Expression Are Associated With Nosocomial Infections in Septic Shock Patients.

Journal: Critical care explorations

Published: March 02, 2023

Inflammation-Induced Coagulopathy Substantially Differs Between COVID-19 and Septic Shock: A Prospective Observational Study.

Inflammation-Induced Coagulopathy Substantially Differs Between COVID-19 and Septic Shock: A Prospective Observational Study.

Journal: Frontiers in medicine

Published: September 21, 2021

sTREM-1 is a specific biomarker of TREM-1 pathway activation.

sTREM-1 is a specific biomarker of TREM-1 pathway activation.

Journal: Cellular & molecular immunology

Published: April 30, 2021

Potentiation of NETs release is novel characteristic of TREM-1 activation and the pharmacological inhibition of TREM-1 could prevent from the deleterious consequences of NETs release in sepsis.

Potentiation of NETs release is novel characteristic of TREM-1 activation and the pharmacological inhibition of TREM-1 could prevent from the deleterious consequences of NETs release in sepsis.

Journal: Cellular & molecular immunology

Published: May 25, 2020

Triggering Receptor Expressed on Myeloid Cells-1 Inhibitor Targeted to Endothelium Decreases Cell Activation.

Triggering Receptor Expressed on Myeloid Cells-1 Inhibitor Targeted to Endothelium Decreases Cell Activation.

Journal: Frontiers in immunology

Published: June 25, 2019

Inhibition of triggering receptor expressed on myeloid cells-1 impairs thrombin generation.

Inhibition of triggering receptor expressed on myeloid cells-1 impairs thrombin generation.

Journal: Journal of thrombosis and haemostasis : JTH

Published: May 27, 2019

Bone marrow vs Wharton's jelly mesenchymal stem cells in experimental sepsis: a comparative study.

Bone marrow vs Wharton's jelly mesenchymal stem cells in experimental sepsis: a comparative study.

Journal: Stem cell research & therapy

Published: April 09, 2019

Clinical-grade mesenchymal stem cells derived from umbilical cord improve septic shock in pigs.

Clinical-grade mesenchymal stem cells derived from umbilical cord improve septic shock in pigs.

Journal: Intensive care medicine experimental

Published: March 01, 2018

Targeted endothelial gene deletion of triggering receptor expressed on myeloid cells-1 protects mice during septic shock.

Targeted endothelial gene deletion of triggering receptor expressed on myeloid cells-1 protects mice during septic shock.

Journal: Cardiovascular research

Published: August 02, 2017

Showing 1-12 of 15

Last Updated: 09/26/2026